Two HEV vaccines are in development. A recombinant vaccine developed in China has proven to be 87% protective over 4.5 years of follow-up. It uses a 30 μg dose in a 3 dose schedule administered at 0, 1 and 6 months and was also found to be safe.^[35] A second recombinant vaccine, evaluated in the Nepalese army and given at a dose of 20 μg at 0, 1 and 6 months, showed a vaccine efficacy of 96% over a shorter period of time.^[36]

Little information exists regarding the efficacy of pre- or post-exposure immune globulin prophylaxis for the prevention of HEV infection. There is at present no proof that immune globulin, including lots produced in countries where HEV infection is endemic, confers protection against HEV infection.^[37]